Romiplostim injection

Romiplostim injection

Form: Injection

Strength: 250mcg/vial, 500 mcg/vial

Reference Brands: Nplate®(US & EU)

Category: Orphan Drugs

Romiplostim injection, marketed as Nplate®, is approved by the FDA and EMA for treating chronic immune thrombocytopenic purpura (ITP). Regulatory dossiers include comprehensive clinical trial data, manufacturing standards, and safety profiles, ensuring high-quality product approval. The dossiers support its efficacy in increasing platelet counts and reducing bleeding risk. Nplate® is administered as a subcutaneous injection, with dosing tailored to patient needs. For detailed information on regulatory processes, dossier submissions, and market approvals in the EU and US, visit PharmaTradz, your trusted source for pharmaceutical regulatory insights and industry updates.

Get Enquiry Back to Listing
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'

The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.

Related Products

Galsulfase IV

Strength: 1mg/ml

Form: Lyophilized powder for IV

Reference Brands: Vimizim®(US & EU)

View Details Get Enquiry
Alglucosidase Alfa IV

Strength: 50 mg/vial

Form: Lyophilized powder

Reference Brands: Lumizyme®(US & EU)

View Details Get Enquiry
Nitisinone tablets

Strength: 2 mg and 5 mg

Form: Tablets

Reference Brands: Orfadin®

View Details Get Enquiry
Treprostinil IV or SC

Strength: 2 mg (0.1 mg/mL), 4 mg (0.2 mg/mL), 8 mg (0.4 mg/mL), 20 mg (1 mg/mL), 50 mg (2.5 mg/mL), 100 mg (5 mg/mL), 200 mg (10 mg/mL), or 400 mg (20 mg/mL)

Form: SC or Intravenous (IV)

Reference Brands: Remodulin®(US & EU)

View Details Get Enquiry

Subscribe to Our Newsletter

Stay updated on pharma trends and marketplace opportunities.